DB05228InvestigationalSmall molecule
RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.
- Mechanism
- Curator reviewed
RDEA806 binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.
- Primary indication
- For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted.Curator reviewed
- Code names
- RDEA806
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with RDEA806, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account